Press release
Catalyst Biosciences Announces Appointment of Jeanne Jew to its Board of Directors
Seasoned Biopharmaceutical Executive Adds Substantial Corporate Development Expertise SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Catalyst
About this update from Gyre Therapeutics, Inc.
[{"type":"text","content":"Seasoned Biopharmaceutical Executive Adds Substantial Corporate Development Expertise SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the appointment of Jeanne Jew to its Board of Directors. \"We are delighted to welcome Jeanne to our Board of Directors. Jeanne’s deep corporate development expertise will be a tremendous asset as we advance our Protease Medicines pipeline,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. Ms. Jew commented, “I look forward to supporting the company’s continued growth and working with the team on its strategic planning and business development initiatives. Catalyst’s compelling and innovative portfolio of protease medicines address areas of significant unmet medical need for patients.” Ms. Jew brings more than 25 years of corporate development experience to her role. She has served as the Chief Business Officer of ALX Oncology Holdings, Inc., since August 2020. Ms. Jew also currently serves as a QB3 Executive Mentor to early-stage life science companies. Prior to joining ALX, she served for over a decade as Senior Vice President, Business Development of Paratek Pharmaceuticals, and as Senior Vice President, Business Development for KaloBios Pharmaceuticals where she led corporate development, strategy, and market planning. Ms. Jew was previously Vice President, Corporate and Commercial Development at Onyx Pharmaceuticals and was responsible for executing the company’s co-promotion collaboration. Earlier in her career, Ms. Jew also held business development positions at Coulter Pharmaceutical, Scios, Inc. and Genentech, Inc. Ms. Jew holds a B.A.in Psychology from Wesleyan University and an M.B.A. from Cornell University. About Catalyst Biosciences, the Protease Medicines companyCatalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform has generated two late-stage clinical programs, including MarzAA, a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. Our complement pipeline includes a preclinical C3-degrader program licensed to...